Hillstream Biopharma Financials

Hillstream Biopharma Stock Summary

Hillstream Biopharma competes with Virax Biolabs, Revelation Biosciences, Kiora Pharmaceuticals, ZyVersa Therapeutics, and Palisade Bio. Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death for the treatment resistant cancers. The company was incorporated in 2017 and is based in Bridgewater, New Jersey. Hillstream Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1 people.

Hillstream Biopharma Key Financial Ratios

Hillstream Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Hillstream Biopharma's current stock value. Our valuation model uses many indicators to compare Hillstream Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Hillstream Biopharma competition to find correlations between indicators driving Hillstream Biopharma's intrinsic value. More Info.Hillstream Biopharma is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Hillstream Biopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

If you are still planning to invest in Hillstream Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Hillstream Biopharma's history and understand the potential risks before investing.